Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Drive: Drug Pricing
JUNE 12, 2024
The negative results from the Phase 3 study, called Ciffreo, come a little more than a month after Pfizer said a patient died in another trial of the gene therapy.
Let's personalize your content